We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Efficacy and safety of 1-month postpartum zidovudine-didanosine to prevent HIV-resistance mutations after intrapartum single-dose nevirapine.
- Authors
Lallemant, Marc; Ngo-Giang-Huong, Nicole; Jourdain, Gonzague; Traisaithit, Patrinee; Cressey, Tim R; Collins, Intira J; Jarupanich, Tapnarong; Sukhumanant, Thammanoon; Achalapong, Jullapong; Sabsanong, Prapan; Chotivanich, Nantasak; Winiyakul, Narong; Ariyadej, Surabon; Kanjanasing, Annop; Ratanakosol, Janyaporn; Hemvuttiphan, Jittapol; Kengsakul, Karun; Wannapira, Wiroj; Sittipiyasakul, Veerachai; Pornkitprasarn, Witaya; Liampongsabuddhi, Prateung; McIntosh, Kenneth; Van Dyke, Russell B; Frenkel, Lisa M; Koetsawang, Suporn; Le Coeur, Sophie; Kanchana, Siripon; PHPT-4 Study Team
- Abstract
Intrapartum single-dose nevirapine plus third trimester maternal and infant zidovudine are essential components of programs to prevent mother-to-child transmission of human immunodeficiency virus (HIV) in resource-limited settings. The persistence of nevirapine in the plasma for 3 weeks postpartum risks selection of resistance mutations to nonnucleoside reverse-transcriptase inhibitors (NNRTIs). We hypothesized that a 1-month zidovudine-didanosine course initiated at the same time as single-dose nevirapine (sdNVP) would prevent the selection of nevirapine-resistance mutations.
- Publication
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2010, Vol 50, Issue 6, p898
- ISSN
1537-6591
- Publication type
Journal Article
- DOI
10.1086/650745